Bolstering the activity of a master cell responsible for coordinating the body’s immune defenses after a tuberculosis infection could help reduce millions of new infections every year.
“The immune response to the TB bacteria hinges on the early response of this cell, and that opens up a whole new avenue for TB control,” says Shabaana Abdul Khader, professor and interim head of the molecular microbiology department at the Washington University in St. Louis School of Medicine and co-senior author of a paper in Nature.
“Now we can start thinking about ways to target this cell to help the body fight off the bacteria before they get a chance to establish themselves.”
Warn the immune system
About 1.5 million people died of TB in 2017, making it the most lethal infectious disease worldwide, according to the World Health Organization.
While a TB vaccine is available, it only provides good protection against the more severe forms of the disease in young children and is less effective in older children and adults. Despite wide use, the vaccine has failed to halt transmission of the disease. The TB bacteria infects a quarter of the world’s population.
“Positive results from several recent vaccine trials make this an exciting time to be working in TB immunology,” says co-senior author Alasdair Leslie, a faculty member at the Africa Health Research Institute. “The more we can understand about the interaction between the bacteria that cause TB and people, the more chance we have of building on these gains and defeating this deadly epidemic.”
Vaccines present bits of dangerous microbes to adaptive immune cells to warn the immune system about them. These cells remember what they’ve seen and respond rapidly if and when such microbes show up—ideally before the microbes multiply and cause disease. But in the case of TB, adaptive immunity alone, even when primed by vaccination, may be too slow to protect people.
Remember me?
For the new study, researchers studied animals and people to identify the immune cells and proteins that defend the body against the TB bacteria in the first days after infection.
They found that cells known as group 3 innate lymphoid cells (ILC3) play a pivotal role in the first two weeks of infection. ILC3 cells belong to the innate branch of the immune system that detects and responds to foreign invaders in the body. Biologists have long believed that the innate immune system lacks memory for specific microbes, but recent studies suggest that some innate immune cells may have memory.
Experiments showed that within five days of infection, ILC3 cells show up in the lungs, where they release chemical compounds that activate and attract other immune cells. The arriving cells include other innate immune cells—which come loaded with bacteria-killing weapons—as well as adaptive immune cells that direct and enhance the innate immune cells’ killing potential. Together, the immune cells surround the bacteria and destroy them.
In mice that lack ILC3 cells, immune responses struggle to get off the ground. The activating chemical compounds release later, immune cells arrive more slowly in the lungs, immune cells don’t engulf the bacteria, and consequently, the mice are sicker and have more TB bacteria in the lungs.
When the researchers gave ILC3 cells to mice that lacked their own ILC3 cells, it jump-started the immune response, and the bacterial numbers never rose very high.
“These innate lymphoid cells seem to orchestrate all the early downstream immune responses—both innate and adaptive—that you need to control infection,” says Khader, who is also a professor of pathology and immunology.
TB, cancer, and other diseases
In people and animals sick with TB disease, ILC3 cells congregated in the lungs, especially in immune structures that surrounded and killed bacteria. After successful treatment with antibiotics, ILC3 cells became more plentiful in their bloodstream, suggesting that the lungs no longer needed the cells to fight infection.
Vaccine developers have largely ignored the innate immune system since they thought it lacked the ability to remember specific microbes. But recent studies show that innate immune cells may have memory or can be trained to be more effective, thereby fortifying the body’s innate immune defenses and providing wide-ranging protection.
Scientists developed the TB vaccine—known as the BCG vaccine—a century ago and designed it to target the adaptive immune system. But they now think it trains the innate immune system.
“Children who get the BCG vaccine are protected not only against TB but many different infectious diseases and cancer for a few years,” Khader says. “They have lower rates of sickness and death from all causes than children who weren’t vaccinated. We wouldn’t want to replace the BCG vaccine, but we may be able to find a compound that we can use to boost immunity in vaccinated children, when the effects of the BCG start to wear off.”
Khader’s group has begun screening a set of chemical compounds, looking for ones that enhance ILC3 activity and drive a stronger immune response in the first days after infection.
“It’s still an open question whether ILCs in the lung are trainable or have memory and how long the training or memory would last,” Khader says. “But if we can train them and get a population of these cells primed and ready to go in the lung, that might be one way we can make a more effective vaccine for TB.”
Amanda Ardain, a graduate student in Leslie’s lab, and Racquel Domingo-Gonzalez and Shibali Das, both postdoctoral researchers in Khader’s lab are co-first authors of the paper.
The National Institutes of Health, the National Heart, Lung and Blood Institute; the Stephen I. Morse Fellowship; the University of Rochester; the Searle Scholars Program; the Beckman Young Investigator Program; the Bill and Melinda Gates Foundation; the Ragon Institute; the National Science Foundation; and the Hugh Hampton Young Memorial Fund Fellowship funded the work.
